Cover Image
市場調查報告書

乾癬 : 開發平台分析

Psoriasis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 232784
出版日期 內容資訊 英文 648 Pages
訂單完成後即時交付
價格
Back to Top
乾癬 : 開發平台分析 Psoriasis - Pipeline Review, H1 2017
出版日期: 2017年04月28日 內容資訊: 英文 648 Pages
簡介

所謂乾癬是指影響皮膚的慢性自體免疫性疾病,是由於細胞乾燥產生斑塊並引起發炎。症狀有以細胞脫落為首的皮膚腫、發癢、產生燒灼感。相關的危險因子有遺傳、特定藥劑的副作用、壓力、傳染病、環境狀況等。除此之外尚有免疫系統機能異常造成乾癬惡化。可用局部或全身用藥、光線治療等來控制症狀。

本報告提供乾癬的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊,以及最新的新聞和發表等訊息。

簡介

  • 乾癬 概要

治療藥的開發

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

治療藥的評估

藥物簡介

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9190IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Psoriasis - Pipeline Review, H1 2017, provides an overview of the Psoriasis (Immunology) pipeline landscape.

Psoriasis is a chronic skin condition caused by an overactive immune system. Symptoms of the disease include shedding of cells, flared up skin, itchiness, and burning sensation, swollen and stiff joints. Predisposing factors include heredity, side effects of certain medicines, stress, infections and environmental conditions. The condition may be controlled by topical or systemic medications and phototherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Psoriasis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Psoriasis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Psoriasis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 14, 1, 21, 44, 42, 1, 103, 32 and 9 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 6 molecules, respectively.

Psoriasis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Psoriasis (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Psoriasis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Psoriasis (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Psoriasis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Psoriasis (Immunology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Psoriasis (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Psoriasis (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Psoriasis - Overview
  • Psoriasis - Therapeutics Development
  • Psoriasis - Therapeutics Assessment
  • Psoriasis - Companies Involved in Therapeutics Development
  • Psoriasis - Drug Profiles
  • Psoriasis - Discontinued Products
  • Psoriasis - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Psoriasis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..10), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..11), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..12), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..13), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..14), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Psoriasis - Pipeline by 3SBio Inc, H1 2017
  • Psoriasis - Pipeline by AbbVie Inc, H1 2017
  • Psoriasis - Pipeline by Abeome Corp, H1 2017
  • Psoriasis - Pipeline by AbGenomics International Inc, H1 2017
  • Psoriasis - Pipeline by Addex Therapeutics Ltd, H1 2017
  • Psoriasis - Pipeline by Adello Biologics LLC, H1 2017
  • Psoriasis - Pipeline by Advinus Therapeutics Ltd, H1 2017
  • Psoriasis - Pipeline by Affibody AB, H1 2017
  • Psoriasis - Pipeline by Albireo Pharma Inc, H1 2017
  • Psoriasis - Pipeline by Alfacyte Ltd, H1 2017
  • Psoriasis - Pipeline by Allergan Plc, H1 2017
  • Psoriasis - Pipeline by Almirall SA, H1 2017
  • Psoriasis - Pipeline by Alteogen Inc, H1 2017
  • Psoriasis - Pipeline by Alvotech Iceland, H1 2017
  • Psoriasis - Pipeline by Amgen Inc, H1 2017
  • Psoriasis - Pipeline by Anacor Pharmaceuticals Inc, H1 2017
  • Psoriasis - Pipeline by AnaptysBio Inc, H1 2017
  • Psoriasis - Pipeline by ApoPharma Inc, H1 2017
  • Psoriasis - Pipeline by Arbor Pharmaceuticals LLC, H1 2017
  • Psoriasis - Pipeline by Arena Pharmaceuticals Inc, H1 2017
  • Psoriasis - Pipeline by Argos Therapeutics Inc, H1 2017
  • Psoriasis - Pipeline by Arrien Pharmaceuticals LLC, H1 2017
  • Psoriasis - Pipeline by AstraZeneca Plc, H1 2017
  • Psoriasis - Pipeline by Athenex Inc, H1 2017
  • Psoriasis - Pipeline by Atlantic Bio Sci LLC, H1 2017
  • Psoriasis - Pipeline by Aurigene Discovery Technologies Ltd, H1 2017
  • Psoriasis - Pipeline by Aurinia Pharmaceuticals Inc, H1 2017
  • Psoriasis - Pipeline by Bayer AG, H1 2017
  • Psoriasis - Pipeline by Beta Pharma Inc, H1 2017
  • Psoriasis - Pipeline by BioApex sro, H1 2017
  • Psoriasis - Pipeline by Biocad, H1 2017
  • Psoriasis - Pipeline by Biocon Ltd, H1 2017
  • Psoriasis - Pipeline by BioLingus AG, H1 2017
  • Psoriasis - Pipeline by BioMAS Ltd, H1 2017
  • Psoriasis - Pipeline by Biomics Biotechnologies Co Ltd, H1 2017
  • Psoriasis - Pipeline by Bionomics Ltd, H1 2017
  • Psoriasis - Pipeline by Bionovis SA, H1 2017
  • Psoriasis - Pipeline by BirchBioMed Inc, H1 2017
  • Psoriasis - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Psoriasis - Pipeline by Brickell Biotech Inc, H1 2017
  • Psoriasis - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Psoriasis - Pipeline by C4X Discovery Holdings PLC, H1 2017
  • Psoriasis - Pipeline by CalciMedica Inc, H1 2017
  • Psoriasis - Pipeline by Can-Fite BioPharma Ltd, H1 2017
  • Psoriasis - Pipeline by Celgene Corp, H1 2017
  • Psoriasis - Pipeline by Cell Medica Ltd, H1 2017
  • Psoriasis - Pipeline by Cellceutix Corp, H1 2017
  • Psoriasis - Pipeline by ChemoCentryx Inc, H1 2017
  • Psoriasis - Pipeline by Chipscreen Biosciences Ltd, H1 2017
  • Psoriasis - Pipeline by ChironWells GmbH, H1 2017
  • Psoriasis - Pipeline by Coherus BioSciences Inc, H1 2017
  • Psoriasis - Pipeline by Compugen Ltd, H1 2017
  • Psoriasis - Pipeline by Concenter BioPharma Silkim Ltd, H1 2017
  • Psoriasis - Pipeline by Crescita Therapeutics Inc, H1 2017
  • Psoriasis - Pipeline by CritiTech Inc, H1 2017
  • Psoriasis - Pipeline by Curapel Ltd, H1 2017
  • Psoriasis - Pipeline by Dermala Inc, H1 2017
  • Psoriasis - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittle, H1 2017
  • Psoriasis - Pipeline by DURECT Corp, H1 2017
  • Psoriasis - Pipeline by EA Pharma Co Ltd, H1 2017
  • Psoriasis - Pipeline by Eli Lilly and Company, H1 2017
  • Psoriasis - Pipeline by ELORAC Inc, H1 2017
  • Psoriasis - Pipeline by Exicure Inc, H1 2017
  • Psoriasis - Pipeline by Foamix Pharmaceuticals Ltd, H1 2017
  • Psoriasis - Pipeline by Forward Pharma A/S, H1 2017
  • Psoriasis - Pipeline by Galapagos NV, H1 2017
  • Psoriasis - Pipeline by Galderma SA, H1 2017
  • Psoriasis - Pipeline by Galectin Therapeutics Inc, H1 2017
  • Psoriasis - Pipeline by Gem Pharmaceuticals LLC, H1 2017
  • Psoriasis - Pipeline by Genentech Inc, H1 2017
  • Psoriasis - Pipeline by Genor BioPharma Co Ltd, H1 2017
  • Psoriasis - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Psoriasis - Pipeline by GlycoMar Ltd, H1 2017
  • Psoriasis - Pipeline by Grupo Ferrer Internacional SA, H1 2017
  • Psoriasis - Pipeline by HitGen LTD, H1 2017
  • Psoriasis - Pipeline by Huabo Biopharm Co Ltd, H1 2017
  • Psoriasis - Pipeline by Hydra Biosciences Inc, H1 2017
  • Psoriasis - Pipeline by iCo Therapeutics Inc., H1 2017
  • Psoriasis - Pipeline by Immune Pharmaceuticals Inc, H1 2017
  • Psoriasis - Pipeline by Immune Response BioPharma Inc, H1 2017
  • Psoriasis - Pipeline by Immungenetics AG, H1 2017
  • Psoriasis - Pipeline by Immunwork Inc, H1 2017
  • Psoriasis - Pipeline by Japan Tobacco Inc, H1 2017
  • Psoriasis - Pipeline by Jenrin Discovery Inc, H1 2017
  • Psoriasis - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
  • Psoriasis - Pipeline by Johnson & Johnson, H1 2017
  • Psoriasis - Pipeline by Kadmon Corp LLC, H1 2017
  • Psoriasis - Pipeline by KaloBios Pharmaceuticals Inc, H1 2017
  • Psoriasis - Pipeline by Kang Stem Biotech Co Ltd, H1 2017
  • Psoriasis - Pipeline by KPI Therapeutics Inc, H1 2017
  • Psoriasis - Pipeline by Lead Pharma Holding BV, H1 2017
  • Psoriasis - Pipeline by LEO Pharma A/S, H1 2017
  • Psoriasis - Pipeline by Lupin Ltd, H1 2017
  • Psoriasis - Pipeline by Lycera Corp, H1 2017
  • Psoriasis - Pipeline by mAbxience SA, H1 2017
  • Psoriasis - Pipeline by Maruho Co Ltd, H1 2017
  • Psoriasis - Pipeline by Medestea Research & Production SpA, H1 2017
  • Psoriasis - Pipeline by MediGene AG, H1 2017
  • Psoriasis - Pipeline by Merck KGaA, H1 2017
  • Psoriasis - Pipeline by MetrioPharm AG, H1 2017
  • Psoriasis - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
  • Psoriasis - Pipeline by Momenta Pharmaceuticals Inc, H1 2017
  • Psoriasis - Pipeline by Mycenax Biotech Inc, H1 2017
  • Psoriasis - Pipeline by Nimbus Therapeutics LLC, H1 2017
  • Psoriasis - Pipeline by NovaLead Pharma Pvt Ltd, H1 2017
  • Psoriasis - Pipeline by Novan Inc, H1 2017
  • Psoriasis - Pipeline by Novartis AG, H1 2017
  • Psoriasis - Pipeline by Nuevolution AB, H1 2017
  • Psoriasis - Pipeline by Numab Innovation AG, H1 2017
  • Psoriasis - Pipeline by Oncobiologics Inc, H1 2017
  • Psoriasis - Pipeline by OSE Immunotherapeutics, H1 2017
  • Psoriasis - Pipeline by Panacea Biotec Ltd, H1 2017
  • Psoriasis - Pipeline by Pfizer Inc, H1 2017
  • Psoriasis - Pipeline by Pharis Biotec GmbH, H1 2017
  • Psoriasis - Pipeline by Pharmedartis GmbH, H1 2017
  • Psoriasis - Pipeline by Philogen SpA, H1 2017
  • Psoriasis - Pipeline by PinCell srl, H1 2017
  • Psoriasis - Pipeline by Principia Biopharma Inc, H1 2017
  • Psoriasis - Pipeline by Promius Pharma LLC, H1 2017
  • Psoriasis - Pipeline by Protalix BioTherapeutics Inc, H1 2017
  • Psoriasis - Pipeline by Prothena Corp Plc, H1 2017
  • Psoriasis - Pipeline by Provectus Biopharmaceuticals Inc, H1 2017
  • Psoriasis - Pipeline by Qilu Pharmaceutical Co Ltd, H1 2017
  • Psoriasis - Pipeline by RedHill Biopharma Ltd, H1 2017
  • Psoriasis - Pipeline by Reliance Life Sciences Pvt Ltd, H1 2017
  • Psoriasis - Pipeline by Rigel Pharmaceuticals Inc, H1 2017
  • Psoriasis - Pipeline by Rock Creek Pharmaceuticals, Inc., H1 2017
  • Psoriasis - Pipeline by Samumed LLC, H1 2017
  • Psoriasis - Pipeline by Sandoz International GmbH, H1 2017
  • Psoriasis - Pipeline by Sareum Holdings Plc, H1 2017
  • Psoriasis - Pipeline by SBI Biotech Co Ltd, H1 2017
  • Psoriasis - Pipeline by Shulov Innovative Science Ltd, H1 2017
  • Psoriasis - Pipeline by Sigmoid Pharma Ltd, H1 2017
  • Psoriasis - Pipeline by Soligenix Inc, H1 2017
  • Psoriasis - Pipeline by Spherium Biomed SL, H1 2017
  • Psoriasis - Pipeline by sterna biologicals Gmbh & Co KG, H1 2017
  • Psoriasis - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
  • Psoriasis - Pipeline by SWITCH Biotech LLC, H1 2017
  • Psoriasis - Pipeline by Syntrix Biosystems Inc, H1 2017
  • Psoriasis - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Psoriasis - Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017
  • Psoriasis - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
  • Psoriasis - Pipeline by TheraMAB LLC, H1 2017
  • Psoriasis - Pipeline by Tolero Pharmaceuticals Inc, H1 2017
  • Psoriasis - Pipeline by UCB SA, H1 2017
  • Psoriasis - Pipeline by Valeant Pharmaceuticals International Inc, H1 2017
  • Psoriasis - Pipeline by vTv Therapeutics Inc, H1 2017
  • Psoriasis - Pipeline by Wellstat Therapeutics Corp, H1 2017
  • Psoriasis - Pipeline by XBiotech Inc, H1 2017
  • Psoriasis - Pipeline by Yuhan Corp, H1 2017
  • Psoriasis - Dormant Projects, H1 2017
  • Psoriasis - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Psoriasis - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Psoriasis - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Psoriasis - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Psoriasis - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Psoriasis - Dormant Projects, H1 2017 (Contd..6), H1 2017
  • Psoriasis - Dormant Projects, H1 2017 (Contd..7), H1 2017
  • Psoriasis - Dormant Projects, H1 2017 (Contd..8), H1 2017
  • Psoriasis - Dormant Projects, H1 2017 (Contd..9), H1 2017
  • Psoriasis - Dormant Projects, H1 2017 (Contd..10), H1 2017
  • Psoriasis - Dormant Projects, H1 2017 (Contd..11), H1 2017
  • Psoriasis - Dormant Projects, H1 2017 (Contd..12), H1 2017
  • Psoriasis - Dormant Projects, H1 2017 (Contd..13), H1 2017
  • Psoriasis - Dormant Projects, H1 2017 (Contd..14), H1 2017
  • Psoriasis - Dormant Projects, H1 2017 (Contd..15), H1 2017
  • Psoriasis - Discontinued Products, H1 2017
  • Psoriasis - Discontinued Products, H1 2017 (Contd..1), H1 2017
  • Psoriasis - Discontinued Products, H1 2017 (Contd..2), H1 2017

List of Figures

  • Number of Products under Development for Acromegaly, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top